Clinical Trial Update: Rubeosis Anti-VEGF (RAVE) Trial for Ischemic Central Retinal Vein Occlusion [Phase 1]

View source ↗

Summary

Phase 1 trial of Rubeosis Anti-VEGF (RAVE) for ischemic central retinal vein occlusion has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ischemic Central Retinal Vein Occlusion

Drugs mentioned

• Rubeosis Anti-VEGF (RAVE)

Snippet

Sponsor: Greater Houston Retina Research | Conditions: Ischemic Central Retinal Vein Occlusion | Phase 1 | Status: COMPLETED